Renate K.
- Country
- Estonia
- Department
- Haematology Centre
Research Overview
- R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)
- A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(waveLINE-004)
Data & Insights
Has run more than one trial at 6 of 65 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment and research of Diffuse Large B-Cell Lymphoma, focusing on innovative therapeutic approaches in hematologic malignancies.
- Lymphoma Management
- B-Cell Malignancies
- Novel Treatment Combinations
The investigator's work encompasses evaluation of targeted therapeutic strategies for aggressive lymphomas, with particular attention to optimizing treatment outcomes in DLBCL patients.
Therapeutic Innovation
Active involvement in advancing combination therapy approaches for hematologic cancers, with specific interest in developing more effective treatment regimens.
- Treatment Optimization
- Comparative Efficacy Studies
- Clinical Outcomes Research
The research focus includes evaluation of modified therapeutic protocols aimed at improving standard treatment approaches in lymphoma care.
Clinical Development
Expertise in conducting therapeutic comparison studies to advance treatment standards in hematologic oncology.
- Treatment Protocol Development
- Efficacy Assessment
- Patient-Centered Outcomes
The investigator's work contributes to establishing enhanced therapeutic strategies for aggressive lymphomas through clinical research initiatives.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.